Nrf2 Modulation by Natural Compounds in Aging, Neurodegeneration, and Neuropathic Pain

Read full text
Authors: Jurga Bernatonienė, Dalia M. Kopustinskienė, Roberto Casale, Alessandro Medoro, Sergio Davinelli, Luciano Saso, Kęstutis Petrikonis
Cited by: 8
References: 238

Abstract

This review summarizes the role of nuclear factor erythroid 2–related factor 2 (Nrf2) as a common link between aging, neurodegeneration, and neuropathic pain. Aging is characterized by oxidative stress and constant inflammation, which coincides with reduced Nrf2 activity and weaker antioxidant responses, increasing vulnerability to diseases. In neurodegenerative disorders—including Alzheimer’s, Parkinson’s, Huntington’s disease, and amyotrophic lateral sclerosis—evidence indicates that impaired Nrf2 signaling contributes to oxidative damage, neuroinflammation, and mitochondrial dysfunction. Furthermore, in neuropathic pain, similar mechanisms are involved, and Nrf2 could play a role as a potential analgesic target because of its role in regulating cellular defense pathways. We also review natural Nrf2 modulators (e.g., flavonoids, other polyphenols, terpenoids, alkaloids), discussing their benefits alongside common translational limitations such as poor solubility, low oral bioavailability, rapid metabolism, and potential safety issues, including possible pro-oxidant effects and chemoresistance. We also outline future directions that should prioritize improving delivery systems, addressing NRF2/KEAP1 gene variations, evaluating combinations with standard therapies, exploring preventive applications, and defining dosing, treatment duration, and long-term safety. Overall, current evidence indicates that Nrf2 modulation is a practical, cross-cutting approach relevant to healthy aging and disease management.

Fields of Study & Subjects

Genomics phytochemicals and oxidative stress Sirtuins and Resveratrol in Medicine Amyotrophic Lateral Sclerosis Research

Publication details

Journal / source
Pharmaceutics
Publisher
MDPI AG
Volume
18
Issue
1
Pages
118–118
Publication date
16 January 2026
Language
EN